An ever growing amount of genomic and pharmacogenomic data on cancer tissue and cell lines reveals the enormous heterogeneity and complexity of the disease but it also holds the promise to inform new strategies for its targeted and patient-specific treatment. It is due to technical limitations that the “cancer”-proteome has yet remained largely untapped in these studies. However, we believe that this data has an immense potential to improve our understanding of the basic principles underlying cancer and to guide us to new approaches in treating the diseases as the proteome is a cell’s functional entity and virtually all targeted therapeutics in cancer treatment are targeting proteins.
In this webinar, we show that the use of TMT-10 reagents for quantitative proteomics on 32 breast cancer cell lines using a synchronous precursor selection supported MS3 method on the Thermo Scientific™ Orbitrap™ Fusion™ mass spectrometer allows us to overcome throughput limitations in quantitative proteomics by enabling the quantification of almost 8000 proteins in only 4.5 hours per cell line.
We believe that this technology puts proteomics in a position to be used side by side with genomics tools in studying complex diseases that require the analyses of a large number of samples.
Key learning objectives
- Multiplexed quantitation using isobaric tags such as tandem mass tags (TMT)
- The future of quantitative proteomics with respect to pathologies such as cancer
- The use of TMT-10 reagents and the Thermo Scientific™ Orbitrap™ Fusion™ mass spectrometer to overcome throughput limitations
Who should attend
- Protein and peptide biochemists
- Cancer cell biologists, biochemists, and biopharmaceutical scientists
- Medical Geneticists
- Mass spectrometrists
- Molecular immunologists
- Core lab directors
- Anyone with interest in multiplexed quantitation
Dr. Wilhelm Haas, PhD Dr. Haas was recruited as an Assistant Professor of Medicine at the Massachusetts General Hospital (MGH) Cancer Center and Harvard Medical School in Boston in 2013 and he is an expert in mass spectrometry-based proteomics. Born in Austria he did his undergraduate and graduate work at the University of Graz, Austria, studying small molecule natural products and getting fascinated about mass spectrometry. He then worked as a postdoctoral fellow in the laboratory of Dr. Steven Gygi at Harvard Medical School, where, among other things, he worked on new technologies enabling multiplexed quantitative proteomics. His lab at the MGH Cancer Center is now using these technologies to study various questions in cancer research, including the search of biomarkers and novel drug targets to improve personalized therapies for cancer.